Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2018 | Future therapies for AML: bispecifics and small molecule inhibitors

Farhad Ravandi • 4 May 2018
ESH AL 2018
Acute Myeloid Leukemia Leukemia Antibodies Blinatumomab Enasidenib Gemtuzumab ozogamicin Ivosidenib Midostaurin Venetoclax

With the recent maturation of novel therapies for acute myeloid leukemia (AML), the field of AML therapeutics is rapidly progressing. In this interview, Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the recently approved small molecule and antibody-based therapies in this field, and the types of therapy that are likely to be approved in the future. This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

More from Farhad Ravandi

1:23
The value of MRD as a marker for disease eradication in AML
Farhad Ravandi • 8 Dec 2023
1:31
Azacitidine and venetoclax plus gilteritinib in the treatment of FLT3-mutated AML
Farhad Ravandi • 8 Dec 2023
1:29
Poor outcomes of patients with AML who relapse underscores the need for effective initial treatment
Farhad Ravandi • 8 Dec 2023
1:43
Nelarabine, PEG-asparaginase and venetoclax added to HCVAD in T-ALL/T-LBL
Farhad Ravandi • 8 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals